The sum of payment has not been published but under the terms of the agreement, Alcon Manufacturing will make an up front payment to NovaCal. Alcon will also make ongoing payments associated with the achievement of development milestones and approval of products incorporating Aganocide compounds.
Alcon will provide research funding to NovaCal as part of a collaborative research program. Additionally, Alcon will be responsible for all clinical development costs and NovaCal will receive royalties on the sales of products containing any Aganocide compound.
NovaCal retains all rights to the Aganocide compounds and also retains the right to co-market products resulting from the agreement for ear and sinus infections in major markets in Asia.
“We believe our partnership with Alcon is a major step forward in fully developing this new class of non-antibiotic anti-infective compounds,” said Dr Ron Najafi, Chairman and CEO of NovaCal.
“NovaCal’s Aganocide compounds are of great interest to us because of their broad application to bacterial and viral infections as well as their potential in multiple therapeutic areas,” said Scott Krueger, Alcon’s vice president R&D for pharmaceutical development. “These are novel compounds that are currently unexampled in topical treatment of infections in the eye, ear and sinus.”
Aganocide is a product that treats infections of the eye, ear and sinus, including those associated with persistent bacterial biofilms.